Overview

A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）

Status:
Not yet recruiting
Trial end date:
2025-03-11
Target enrollment:
Participant gender:
Summary
This is a Phase I study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, LB1410, is safe, tolerable and efficacious in participants with advanced solid tumors or lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
L & L biopharma Co., Ltd., Shanghai China